Healthcare M&A Heats Up as Analysts Lift Pharma Targets

Gilead's $2.18B Ouro deal and Merck's Terns acquisition highlight deal activity.

Healthcare Market Overview

Healthcare equities saw mixed performance this week, with analysts raising price targets across several major names while managed care stocks face near-term earnings uncertainty. $UNH is expected to release fiscal first-quarter earnings next month, with analysts projecting a single-digit profit drop. Analyst commentary emphasized structural resilience in healthcare spending across economic cycles, though recent share performance has been weak for some managed care names.

Big Pharma & Biotech

$GILD announced plans to acquire Ouro Medicines for up to approximately $2.18 billion to expand its inflammation pipeline, according to a March 23 Wall Street Journal report. $MRK received an Outperform rating reiteration from RBC with a $142 price target following a conference call discussing its proposed acquisition of Terns Pharmaceuticals, though RBC noted investor concerns over the "modest premium." Guggenheim raised its price target on $PFE to $36 from $35 with a Buy rating, citing upcoming Phase 3 data from the MEVPRO-1 trial, while $JNJ saw analysts lift price targets to the $250-$280 range, with fair value estimates moving from $237.29 to $241.08.

MedTech & Devices

$TMO drew attention after agreeing to a collaboration with SHL Medical and committing new investment to its Ridgefield, New Jersey facility to create an integrated U.S. hub for drug device combination products. The move follows TMO's completed Clario acquisition, with shares at $488.85 showing a 7-day return of 4.0%. $ISRG was highlighted as one of the best pure-play robotics stocks, with the surgical robotics leader maintaining an installed base of over 12,000 Intuitive systems.

Obesity Market Dynamics

The obesity drug market continues to attract investor focus, with $LLY positioned as the GLP-1 market leader while analysts characterized Novo Nordisk as a "durable No. 2" competitor rather than a loser in the world's fastest-growing drug market. Commentary suggested $LLY's market position could deliver long-term shareholder value in the expanding weight-loss therapeutic category.

Looking Ahead

Investors will focus on $UNH's fiscal first-quarter earnings release expected later in April, with single-digit profit declines anticipated. $PFE's upcoming MEVPRO-1 Phase 3 trial data represents a key catalyst, with Guggenheim seeing favorable risk-reward ahead of the readout. M&A integration progress at $GILD and $MRK will be monitored as both companies advance newly announced or proposed transactions.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy